| |
| |
|
| Insider
Information: |
Aselage Steve |
| Relationship: |
Director |
| City: |
Fremont |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
5 |
|
| Direct
Shares |
293,421 |
|
|
Indirect Shares
|
19,500 |
|
|
| Direct
Value |
$6,739,296 |
|
|
|
Indirect Value
|
$118,170 |
|
|
| Total
Shares |
312,921 |
|
|
| Total
Value |
$6,857,466 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
4
|
5
|
|
Stock
price went up :
|
0
|
3
|
| Stock
price went down : |
4
|
2
|
| |
|
|
|
Gain/Loss Ratio : |
-4.0
|
1.5
|
| Percentage
Gain/Loss : |
 -31.1%
|
 62.9%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Cti Biopharma Corporation |
CTIC |
EVP, Global Commercial... |
2005-06-30 |
24,133 |
2004-08-03 |
0 |
Premium* |
|
|
Biomarin Pharmaceutical Inc |
BMRN |
EVP, Chief Business Of... |
2012-07-02 |
59,030 |
2006-04-28 |
0 |
Premium* |
|
|
Travere Therapeutics, Inc |
TVTX |
Director |
2022-05-11 |
146,919 |
2021-11-05 |
19,500 |
Premium* |
|
|
Acer Therapeutics Inc |
ACER |
Director |
2023-11-17 |
0 |
2017-09-19 |
0 |
Premium* |
|
|
Biocryst Pharmaceuticals Inc |
BCRX |
Director |
2023-06-13 |
63,339 |
2019-03-12 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Business Officer |
• – – |
2012-07-02 |
4 |
AS |
$40.00 |
$3,813,800 |
D/D |
(95,345) |
59,030 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Business Officer |
• – – |
2012-07-02 |
4 |
OE |
$17.54 |
$1,672,351 |
D/D |
95,345 |
154,375 |
0 |
- |
|
| TVTX |
Travere Therapeutics, Inc |
Director |
– • – |
2021-10-07 |
4 |
AS |
$26.23 |
$1,574,760 |
D/D |
(60,000) |
189,794 |
0 |
% |
|
| BMRN |
Biomarin Pharmaceutical I... |
SVP, Global Commercial Dev |
• – – |
2008-03-03 |
4 |
S |
$38.00 |
$1,520,000 |
D/D |
(40,000) |
32,034 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Business Officer |
• – – |
2011-05-26 |
4 |
S |
$27.00 |
$1,093,828 |
D/D |
(40,512) |
43,978 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Business Officer |
• – – |
2012-05-11 |
4 |
S |
$37.07 |
$989,348 |
D/D |
(26,160) |
59,030 |
0 |
- |
|
| TVTX |
Travere Therapeutics, Inc |
Director |
– • – |
2021-10-07 |
4 |
OE |
$16.23 |
$973,800 |
D/D |
60,000 |
249,794 |
0 |
- |
|
| TVTX |
Travere Therapeutics, Inc |
Director |
– • – |
2021-11-16 |
4 |
AS |
$29.39 |
$934,602 |
D/D |
(31,800) |
149,494 |
0 |
% |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Business Officer |
• – – |
2010-11-18 |
4 |
S |
$25.87 |
$811,546 |
D/D |
(31,375) |
29,881 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Business Officer |
• – – |
2010-09-08 |
4 |
S |
$22.00 |
$770,000 |
D/D |
(35,000) |
37,587 |
0 |
- |
|
| TVTX |
Travere Therapeutics, Inc |
Director |
– • – |
2021-02-02 |
4 |
AS |
$30.75 |
$768,750 |
D/D |
(25,000) |
196,667 |
0 |
% |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Business Officer |
• – – |
2011-05-26 |
4 |
OE |
$17.33 |
$702,073 |
D/D |
40,512 |
84,490 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
SVP, Global Commercial Dev. |
• – – |
2008-05-06 |
4 |
S |
$37.75 |
$611,550 |
D/D |
(16,200) |
28,665 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
SVP, Global Commercial Dev |
• – – |
2008-03-03 |
4 |
OE |
$7.16 |
$593,640 |
D/D |
65,000 |
72,034 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Business Officer |
• – – |
2011-10-28 |
4 |
AS |
$35.00 |
$590,625 |
D/D |
(16,875) |
46,478 |
0 |
- |
|
| TVTX |
Travere Therapeutics, Inc |
Chief Executive Officer |
• • – |
2015-11-09 |
4 |
AS |
$18.77 |
$563,100 |
D/D |
(30,000) |
338,756 |
0 |
- |
|
| TVTX |
Travere Therapeutics, Inc |
Chief Executive Officer |
• • – |
2015-11-10 |
4 |
AS |
$18.72 |
$561,600 |
D/D |
(30,000) |
308,756 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Business Officer |
• – – |
2010-03-08 |
4 |
S |
$22.11 |
$532,526 |
D/D |
(24,090) |
19,855 |
0 |
- |
|
| ACER |
Acer Therapeutics Inc |
Director |
– • – |
2022-11-29 |
4 |
B |
$1.22 |
$500,000 |
D/D |
409,836 |
483,741 |
2.39 |
% |
|
| TVTX |
Travere Therapeutics, Inc |
Director |
– • – |
2021-03-17 |
4 |
AS |
$27.35 |
$486,456 |
D/D |
(17,727) |
188,940 |
0 |
% |
|
| TVTX |
Travere Therapeutics, Inc |
Director |
– • – |
2020-11-06 |
4 |
AS |
$23.00 |
$474,375 |
D/D |
(20,625) |
213,107 |
0 |
% |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Business Officer |
• – – |
2010-11-18 |
4 |
OE |
$14.39 |
$451,486 |
D/D |
31,375 |
61,756 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Business Officer |
• – – |
2010-09-08 |
4 |
OE |
$11.74 |
$410,900 |
D/D |
35,000 |
72,587 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
SVP, Global Commercial Dev |
• – – |
2007-08-10 |
4 |
S |
$20.21 |
$405,389 |
D/D |
(20,000) |
4,895 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Business Officer |
• – – |
2012-05-15 |
4 |
S |
$38.64 |
$386,373 |
D/D |
(10,000) |
59,030 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
